Paul-Flechsig-Institut für Hirnforschung
 Universitätsmedizin Leipzig

Lymphocyte activation test as blood biomarker for Alzheimer's disease

It is the aim of the project to validate a blood biomarker for the diagnosis of Alzheimer´s disease (AD) as an inexpensive and non-invasive tool which can easily be performed on a large scale at the primary care level and allows to identify patients with high sensitivity at initial stage of AD with mild dementia.

The biomarker is based on AD-associated alterations in the mitogenic response of peripheral lymphocytes. In two previous studies, this biomarker has been assessed in cases with moderate and severe AD. Multivariate scoring demonstrated up to a 90% positive and negative agreement with subject clinical diagnosis. However, here, we will prove this diagnostic tool for its validity in early cases of AD with mild dementia. Herewith, we will contribute to provide measures for detecting patients at very initial stages of the disease which allows for a timely symptomatic treatment and, thus, contributes to a better prognosis.



  • Amarantus BioScience Holdings, Inc. (AMBS)


DAAD - David Larbi Simpong
last update: 11.06.2018, 14:12 Uhr
Zurück zum Seitenanfang springen
Zurück zum Seitenanfang springen
Paul-Flechsig-Institut für Hirnforschung